BamSEC and AlphaSense Join Forces
Learn More

Windtree Therapeutics Inc.

NASDAQ: WINT    
Share price (12/20/24): $0.32    
Market cap (12/20/24): $2.879 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 26 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 55 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 34 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 56 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 19 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 73 pages Common Stock Purchase Agreement Dated as of June 26, 2024 by and Among Windtree Therapeutics, Inc., and Seven Knots, LLC
12/34/56
EX-10.2
from 10-Q 4 pages Amendment No. 1 to Master Services Agreement and Work Order Nos. 11 and 12
12/34/56
EX-10.1
from 10-Q 7 pages Master Services Agreement
12/34/56
EX-10.61
from 10-K 71 pages License, Development and Commercialization Agreement by and Between Windtree Therapeutics, Inc. and Lee’s Pharmaceutical (Hk) Ltd
12/34/56
EX-10.5
from 10-K 6 pages Amendment No. 1 to the License Agreement
12/34/56
EX-10.3
from 10-K 6 pages Amendment No. 1 to Amended and Restated License Agreement
12/34/56
EX-10.2
from 8-K 27 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 55 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 9 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 19 pages Exchange and Termination Agreement
12/34/56
EX-10.1
from 8-K 12 pages Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.29
from 10-K 4 pages Third Amendment to Lease Agreement
12/34/56
EX-10.1
from 8-K 11 pages February 21, 2023 [Name and Address of Warrant Holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants to Whom It May Concern
12/34/56
EX-10.1
from 8-K 11 pages January 20, 2023 [Name and Address of Warrant Holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants to Whom It May Concern
12/34/56
EX-10.1
from 10-Q 57 pages Amended and Restated License, Development and Commercialization Agreement by and Among Windtree Therapeutics, Inc., Lee’s Pharmaceutical (Hk) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd
12/34/56